【全球抗疫】巴西專家：中國疫苗全球領先！_風聞

前段時間，關於中國的新冠疫苗出現了平行時空：

西方主流媒體瘋狂抹黑中國疫苗，同時，很多國家大量購買中國的疫苗，而且很多外國政要也紛紛帶頭接種中國疫苗。

這個世界上，沒有人是傻子。西方媒體的操作無非是意識形態+利益驅動。而菲律賓總統杜特爾特的評論則是一針見血！

中國疫苗在海外的試驗，包括土耳其和印尼的試驗結果也有不少差距。偏偏中國疫苗的生產商深知西方媒體的“德性”，所以懶得向西方媒體解釋。（試驗結果的影響因素有很多，不在此解釋，有興趣的網友可自行了解）

但是，我相信一定有很多網友和我一樣對中國疫苗之謎既不甘（被抹黑）又好奇！經過多番尋找，我終於找到了，下面就為大家解謎！

讓我們把目光聚焦巴西---全球戰疫的主要戰場之一，也是所有疫苗的主要和必要試驗地！

這篇美媒《財富雜誌》的報道雖然不怎麼樣，但是其中對巴西專家的採訪才是我們關注的重點！

科興疫苗Sinovac的巴西合作伙伴是Butantan Institute。

Butantan研究所的醫學主任RicardoPalácios認為，較低的功效率證明了Sinovac科興疫苗在巴西的試驗比Pfizer和Moderna試驗更關注高風險人羣，並且該研究所使用了更嚴格的標準。他説：“我們（在我們的試驗中）增加了所有可能的困難。”

帕拉西奧斯（Palácios）表示，科興疫苗（Sinovac）的相對較低的50％的效率是由於其對被視為試驗志願者的感染的標準更為嚴格。 Butantan研究所表示，其結果包括六種類型的病例：無症狀，非常輕度，輕度，中度和重度兩個級別。 （巴西當局強調，公眾應關注該疫苗在預防COVID-19嚴重病例方面的100％功效。）西方疫苗生產商通常只包括輕度，中度和重度類別，輝瑞公司等公司正在開展更多研究看看疫苗是否可以預防無症狀病例。

帕拉西奧斯説：“人們想比較其他研究，但這就像比較一個人在平坦的伸展運動中跑一公里的比賽和另一個在陡峭且充滿障礙的伸展運動中跑的人。”

有一些證據支持Palácios的説法，即巴西的試驗標準比其他地方進行的試驗更可能捕獲輕度COVID-19病例，這將導致較低的有效率。

在美國食品藥品監督管理局（FDA）對輝瑞疫苗試驗的評估中，該機構發現多達1,594例疑似但未經證實的COVID-19病例。由於尚未確定感染情況，因此沒有將其納入輝瑞疫苗的功效率。

Sinovac’s Brazilian partner, the Butantan Institute.

Ricardo Palácios, medical director of the Butantan Institute, argued that the lower efficacy rate was evidence that Sinovac’s Brazil trials focused on higher risk groups than the Pfizer and Moderna trials and that the institute used more stringent standards. “We added all possible difficulties [to our trials],” he said. 

Palácios said Sinovac’s relatively low efficacy rate of 50% was due to its more rigorous standard for what counts as an infection among trial volunteers. The Butantan Institute said it included six types of cases in its results: asymptomatic, very mild, mild, two levels of moderate, and severe. (The Brazilian authorities stressed that the public should focus on the vaccine’s 100% efficacy in protecting against severe cases of COVID-19.) Western vaccine makers generally included only mild, moderate, and severe categories, and companies like Pfizer are doing additional studies to see if the vaccine will prevent asymptomatic cases.

“People want to compare other studies, but that’s like comparing a person that runs a 1-kilometer race on a flat stretch and another doing it on a steep and obstacle-filled stretch,” Palácios said.

There is some evidence to back up Palácios’ claim that Brazil’s trial standards are more likely to catch mild cases of COVID-19 than trials conducted elsewhere, which would result in a lower efficacy rate.

In the U.S.’s Food and Drug Administration’s evaluation of Pfizer’s vaccine trials, the agency found that there were up to 1,594 suspected but unconfirmed cases of COVID-19. Because the infections were unconfirmed, they didn’t factor into the Pfizer vaccine’s efficacy rate.